Palisade Bio (PALI)
(Delayed Data from NSDQ)
$3.58 USD
-0.01 (-0.28%)
Updated Sep 9, 2024 03:58 PM ET
After-Market: $3.59 +0.01 (0.28%) 6:26 PM ET
3-Hold of 5 3
F Value B Growth D Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$3.58 USD
-0.01 (-0.28%)
Updated Sep 9, 2024 03:58 PM ET
After-Market: $3.59 +0.01 (0.28%) 6:26 PM ET
3-Hold of 5 3
F Value B Growth D Momentum D VGM
Zacks News
Bears are Losing Control Over Palisade Bio (PALI), Here's Why It's a 'Buy' Now
by Zacks Equity Research
Palisade Bio (PALI) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
Palisade (PALI) In-Licenses Rights for IBD Candidate, Stock Up
by Zacks Equity Research
Palisade (PALI) gains on entering into global licensing deal with Giiant Pharma to develop gastrointestinal therapies.
Palisade Bio, Inc. (PALI) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
by Zacks Equity Research
Palisade Bio, Inc. (PALI) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
Palisade Bio, Inc. (PALI) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
by Zacks Equity Research
After losing some value lately, a hammer chart pattern has been formed for Palisade Bio, Inc. (PALI), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
Palisade (PALI) Enrolls First Patient in LB1148 Study in China
by Zacks Equity Research
Palisade's (PALI) development partner, Newsoara, enrolls first patient in the late-stage clinical study of LB1148 to improve postoperative GI function for patients in China.
What Makes Palisade Bio, Inc. (PALI) a New Buy Stock
by Zacks Equity Research
Palisade Bio, Inc. (PALI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Palisade Bio's (PALI) LB1148 Gets FDA Fast-Track Designation
by Zacks Equity Research
Palisade Bio (PALI) gets Fast Track status from the FDA for its lead drug, LB1148, for accelerated return of bowel function following gastrointestinal (GI) surgery.
Palisade Bio, Inc. (PALI) Moves to Buy: Rationale Behind the Upgrade
by Zacks Equity Research
Palisade Bio, Inc. (PALI) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.